Prognostic Factors and Therapeutic Outcomes in 22 Patients with Pleomorphic Xanthoastrocytoma.
10.3340/jkns.2013.53.5.281
- Author:
Sungryong LIM
1
;
Jeong Hoon KIM
;
Sun A KIM
;
Eun Suk PARK
;
Young Shin RA
;
Chang Jin KIM
Author Information
1. Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. jhkim1@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Pleomorphic xanthoastrocytoma;
Prognosis;
outcome;
Radiotherapy
- MeSH:
Disease Progression;
Disease-Free Survival;
Edema;
Headache;
Humans;
Necrosis;
Neurologic Manifestations;
Occipital Lobe;
Prognosis;
Radiotherapy, Adjuvant;
Seizures;
Temporal Lobe
- From:Journal of Korean Neurosurgical Society
2013;53(5):281-287
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: Pleomorphic xanthoastrocytoma (PXA) is a rare primary low-grade astrocytic tumor classified as WHO II. It is generally benign, but disease progression and malignant transformation have been reported. Prognostic factors for PXA and optimal therapies are not well known. METHODS: The study period was January 2000 to March 2012. Data on MR findings, histology, surgical extents and adjuvant therapies were reviewed in twenty-two patients diagnosed with PXA. RESULTS: The frequent symptoms of PXA included seizures, headaches and neurologic deficits. Tumors were most common in the temporal lobe followed by frontal, parietal and occipital lobes. One patient who died from immediate post-operative complications was excluded from the statistical analysis. Of the remaining 21 patients, 3 (14%) died and 7 (33%) showed disease progression. Atypical tumor location (p<0.001), peritumoral edema (p=0.022) and large tumor size (p=0.048) were correlated with disease progression, however, Ki-67 index and necrosis were not statistically significant. Disease progression occurred in three (21%) of 14 patients who underwent GTR, compared with 4 (57%) of 7 patients who did not undergo GTR, however, it was not statistically significant. Ten patients received adjuvant radiotherapy and the tumors were controlled in 5 of these patients. CONCLUSION: The prognosis for PXA is good; in our patients overall survival was 84%, and event-free survival was 59% at 3 years. Atypical tumor location, peritumoral edema and large tumor size are significantly correlated with disease progression. GTR may provide prolonged disease control, and adjuvant radiotherapy may be beneficial, but further study is needed.
